Mesoblast Ltd. (NASDAQ: MESO) Climbs to New 52-Week High

December 19, 2024 09:40:23

Shares of Mesoblast Limited (NASDAQ: MESO) traded at a new 52-week high today and are currently trading at $14.79. So far today, approximately 1.17M shares have been exchanged, as compared to an average 30-day volume of 254.66k shares.

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

Mesoblast Limited share prices have moved between a 52-week high of $19.15 and a 52-week low of $1.61. The stock has moved 4.17% over the past week.

To learn more, visit Mesoblast Limited

Receive IBN News Alerts – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN News Alerts, please visit https://IBN.fm/connected

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]